Successful Treatment with Afatinib after Osimertinib-induced Interstitial Lung Disease in a Patient with EGFR-mutant Non-small-cell Lung Cancer

Osimertinib is the standard treatment for epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer. However, drug-induced interstitial lung disease (ILD) is recognized as a serious adverse event associated with EGFR-tyrosine kinase inhibitors (TKIs). We herein report a 78-year-old w...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Intern Med
Главные авторы: Nishima, Shunichi, Miyanaga, Akihiko, Saito, Sho, Yuasa, Mizuki, Takahashi, Satoshi, Kashiwada, Takeru, Sugano, Teppei, Noro, Rintaro, Minegishi, Yuji, Terasaki, Yasuhiro, Saito, Yoshinobu, Kubota, Kaoru, Seike, Masahiro, Gemma, Akihiko
Формат: Artigo
Язык:Inglês
Опубликовано: The Japanese Society of Internal Medicine 2020
Предметы:
Case Report
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC7946498/
https://ncbi.nlm.nih.gov/pubmed/32999231
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2169/internalmedicine.5435-20
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы